PD-L2: A prognostic marker in chromophobe renal cell carcinoma?

Erlmeier F, Weichert W, Autenrieth M, Wiedemann M, Schrader AJ, Hartmann A, Ivanyi P, Steffens S (2017)

Publication Type: Journal article

Publication year: 2017

Journal

Medical Oncology Humana Press

Book Volume: 34

Pages Range: 71

Journal Issue: 5

DOI: 10.1007/s12032-017-0926-1

Abstract

In the context of cancer immunotherapy, PD-1 as well as PD-L1 has been widely studied in renal cell carcinoma (RCC). PD-1 and PD-L1 play a significant role as prognostic markers in clear cell renal cell carcinoma. In contrast, little is known about PD-L2 expression patterns in RCC, especially in rarer subtypes. The aim of this study was to evaluate the prevalence, distribution and prognostic impact of PD-L2 expression in chromophobe (ch)RCC. Eighty-one patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimens were analyzed for PD-L2 expression by immunohistochemistry. Expression data were associated with clinicopathological parameters and overall survival (OS). Twenty-three (28.4%) patients showed a PD-L2 > median (PD-L2 high) staining intensity. No significant association between clinicopathological parameters and PD-L2 expression was identified. A significant difference between 5- and 10-year OS in dependence of PD-L2 expression was found (PD-L2 low 96.4 and 87.7% vs. PD-L2 high 87.1 and 56%; log rank, p = 0.029). However, in multivariate analysis PD-L2 expression failed to be proofed as an independent prognostic factor. In conclusion, to our knowledge this is the first study evaluating the prognostic impact of PD-L2 in a considerably large cohort of chRCC. Our results showed a significant diminished OS in dependence of PD-L2 expression. This implicates that PD-L2 might play a role as prognostic marker in chRCC demanding further evaluation.

Authors with CRIS profile

Arndt Hartmann Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie

Involved external institutions

KfH-Nierenzentrum Jena DE Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School DE Germany (DE) Ludwig-Maximilians-Universität (LMU) DE Germany (DE) Technische Universität München (TUM) DE Germany (DE)

How to cite

APA:

Erlmeier, F., Weichert, W., Autenrieth, M., Wiedemann, M., Schrader, A.J., Hartmann, A.,... Steffens, S. (2017). PD-L2: A prognostic marker in chromophobe renal cell carcinoma? Medical Oncology, 34(5), 71. https://doi.org/10.1007/s12032-017-0926-1

MLA:

Erlmeier, Franziska, et al. "PD-L2: A prognostic marker in chromophobe renal cell carcinoma?" Medical Oncology 34.5 (2017): 71.

BibTeX: Download